Wolverine Stack: What the Research Shows on BPC-157 and TB-500

The Wolverine stack is two peptides, BPC-157 and TB-500, used together. Named after the fast-healing Marvel comics character, it has a following in fitness and sports recovery circles, where it is believed to speed up the repair of tendons, ligaments, muscle and skin. Each peptide has substantial animal research behind it, but the combination has almost no direct study. Neither is approved for human use by the MHRA or FDA, and both are supplied for laboratory research only.

What is the Wolverine stack?

The Wolverine stack is BPC-157 and TB-500 used together, supplied either as two separate vials or as a single pre-mixed blend. It pairs a 15-amino-acid peptide based on a gastric protein with a synthetic fragment of thymosin beta-4, two compounds studied through different biological pathways. Sometimes shortened to the Wolverine peptide, the stack combines two research compounds with separate evidence records.

What is BPC-157

BPC-157 is a pentadecapeptide, a chain of 15 amino acids based on a larger protective protein found in human gastric juice (the full sequence is listed on the product page). It has been studied in preclinical models of tissue injury, inflammatory bowel disease and central nervous system disorders, which a 2025 literature and patent review summarises alongside its proposed mechanisms of action. For how it compares with another peptide studied in inflammation research, see our KPV vs BPC-157 research comparison. 

What is TB-500?

TB-500 is a synthetic peptide known by its amino acid code, Ac-LKKTETQ. Esposito and colleagues (2012) identified it as a fragment of human thymosin beta-4, a 43-amino-acid protein that binds actin, which cells use to change shape and move. The fragment matches the protein’s actin-binding site, linked in research to cell migration and wound healing. Most human trials used full-length thymosin beta-4 rather than TB-500, so their findings do not automatically transfer. One mouse study found the fragment repaired skin wounds comparably to the full protein, the closest direct comparison available. 

Why researchers pair BPC-157 and TB-500

The case for the stack is that the two compounds act on different stages of repair. In cell studies, BPC-157 increased tendon fibroblast migration and survival, and other work links it to nitric oxide signalling in blood vessel cells. Thymosin beta-4 research centres on cell migration and angiogenesis. Together, the argument runs that TB-500 and BPC-157 should act on more of the repair process at once. It is a reasonable hypothesis that no controlled study has tested.

What the combination research actually shows

The only human data that includes both compounds is a 16-patient chart review with no control group. In that retrospective study of knee injections, Lee and Padgett (2021) reported that 4 patients received BPC-157 with thymosin beta-4 and 12 received BPC-157 alone. Pain relief was reported in 3 of 4 and 11 of 12, respectively, but with only four patients and no comparison group cannot be shown whether the combination added anything. 

BPC-157 and TB-500 benefits: what studies have shown so far

Nearly all research on the Wolverine stack’s two compounds comes from animal and cell models.

Tendon, ligament and muscle models

Tendon research is one of the more developed areas of the BPC-157 literature. In rats, it improved strength, function and collagen formation in transected Achilles tendons, as well as tendon-to-bone healing and healing where muscle meets tendon. Direct tendon research on TB-500 is sparse.

Wound and vascular models

BPC-157 has been studied in gut injury models and in skin wound models, including burns and diabetic ulcers. The foundational thymosin beta-4 study found it increased wound re-epithelialisation by up to 61% over controls in rats, with more collagen and new blood vessel growth.

Human data so far

BPC-157 has three small published human studies, none placebo-controlled, and no completed Phase II trial. Full-length thymosin beta-4 has reached Phase II trials in pressure and stasis ulcers and dry eye, but none used TB-500.

BPC-157 and TB-500 dosage in published research

Neither compound in the Wolverine stack has an established human dose, alone or combined, and BPC-157 has no validated dosing regimen. The doses below come from animal studies and describe experimental conditions, not doses for people. 

In a rat Achilles tendon model, Staresinic and colleagues (2003) injected BPC-157 intraperitoneally at 10 µg/kg, 10 ng/kg or 10 pg/kg daily, a million-fold range that shows how far these studies are from defining a working dose. A 2021 myotendinous junction study used 10 µg/kg or 10 ng/kg by injection, or BPC-157 in the rats’ drinking water. For thymosin beta-4, Malinda and colleagues (1999) applied 5 µg of the full-length protein to rat skin wounds, or injected 60 µg every other day. 

Animal doses also cannot be converted into human ones:

• Species differ: BPC-157’s intramuscular bioavailability was 14% to 19% in rats and 45% to 51% in dogs.
• Scaling only starts a trial: conversion formulas help set cautious starting doses for supervised first-in-human trials, as in the FDA’s starting dose guidance. They do not establish safe or effective doses.
• The fragment is not the protein: thymosin beta-4 doses do not describe TB-500.

Dosing figures online come from forums and clinics rather than controlled trials, so we do not reproduce them.

Fixed-ratio blends versus separate vials

Pre-mixed blends use a fixed ratio, typically equal amounts of each. That is a manufacturing decision: no study has tested an optimal ratio, because none has tested the combination.

BPC-157 and TB-500 side effects: what has been reported

No study has recorded side effects of the Wolverine stack’s two compounds used together.

BPC-157 side effects in published research

A preclinical toxicology study in mice, rats, rabbits and dogs found no serious toxicity, mild injection-site irritation and a reversible fall in creatinine in dogs at 2 mg/kg. In a two-person intravenous pilot, there were no side effects or changes in organ function markers, but two people cannot establish a safety profile.

TB-500 side effects in published research

There is no published human safety study of TB-500. In 40 healthy volunteers given intravenous full-length thymosin beta-4, adverse events were infrequent and mild or moderate, but that is a different molecule made to pharmaceutical standards.

What is still unknown

• Long-term and combined effects: neither has been studied.
• Tumour growth (theoretical): both compounds are studied for promoting blood vessel growth. In mice, melanoma cells engineered to overproduce thymosin beta-4 formed larger tumours, which points to a mechanism rather than a demonstrated risk.
• Material quality: unregulated material may not match its label.

How to use BPC-157 and TB-500 in a laboratory setting

Both compounds are supplied as freeze-dried powder. This section covers laboratory handling only.

1. Store: keep unopened vials at around -20 °C.
2. Check the batch: match the label’s batch ID to its certificate of analysis on our independent testing page.
3. Reconstitute: add bacteriostatic water slowly down the vial wall and swirl gently. Diluent volumes are listed on each product page.
4. Store after reconstitution: keep at 2 to 8 °C and avoid repeated freeze-thaw cycles.

Separate vials allow independent concentrations and single-compound control groups. A blend fixes the ratio, and we found no published stability data for the two in one solution.

Regulatory status of BPC-157 and TB-500 in the UK

• MHRA: neither is a licensed medicine in the UK, where licensing is overseen by the MHRA.
• FDA: neither is approved. In July 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend both for the 503A bulks list of substances US compounding pharmacies may use. The vote is non-binding and is not drug approval, and FDA presenters raised concerns about what products sold under these names actually contain.
• WADA: both are prohibited at all times, BPC-157 under S0 and TB-500 under S2.3.
• UK research supply: both are sold in the UK for laboratory research, not human consumption.

Order the Wolverine Stack from River Peptides

Every Wolverine stack from River Peptides is independently tested and supplied for laboratory research use. The two-vial Wolverine stack contains 10mg of BPC-157 and 10mg of TB-500 in separate lyophilised vials, giving independent control of each compound, while the pre-mixed BPC-157 + TB500 blend combines both peptides for single-vial preparation. 

Each batch is analysed by Janoshik Laboratories and Analiza Biatek, using HPLC to confirm the purity of each peptide and mass spectrometry to verify that its molecular identity matches the label, with certificates of analysis published against each batch ID on our independent testing page. We also hold ISO 9001 and ISO 14001 certification. Standalone BPC-157 and TB-500 vials are also available, along with related compounds in our Healing & Recovery range.

Wolverine Stack FAQs

Is the Wolverine stack the same as a BPC-157 and TB-500 blend?

Yes. The Wolverine stack is BPC-157 and TB-500 together, sold either as a pre-mixed blend or as two separate vials.

Can BPC-157 and TB-500 be mixed in the same vial?

They are sold pre-mixed, but we found no published stability data for the two in a single solution.

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a seven-amino-acid fragment of the 43-amino-acid protein, and research on the full protein does not automatically apply to it.

Is the Wolverine stack legal in the UK?

Both compounds are sold for laboratory research. Neither is a licensed medicine or approved for human consumption. 

Is the Wolverine stack banned in sport?

Yes. WADA prohibits both at all times: BPC-157 under S0 and TB-500 under S2.3.

Has the FDA approved BPC-157 or TB-500?

No. A July 2026 FDA advisory vote recommended both for US compounding use, but it is non-binding and is not drug approval.